Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment

Completed · Phase 1

Conditions studied: Hepatic Insufficiency

In brief

The purpose of this study is to assess the effects of hepatic impairment on the single dose pharmacokinetics of BMS-790052.

Key facts

Study ID

NCT00859053

Run by

Bristol-Myers Squibb

People needed

46

Starts

2009-03-01

Expected to finish

2009-09-01

Last updated by the study team

2015-10-08

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

Where it is running

• Advanced Clinical Research Institute — Anaheim, California, United States
• Orlando Clinical Research Center — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.